On November 19, 2020 Alphamab Oncology and 3D Medicines reported that it filed a China NDA for their partnered anti-PD-L1 therapy as a treatment for MSI-H/dMMR cancer (Press release, Alphamab, NOV 19, 2020, View Source [SID1234571462]). In a Phase II registration trial, patients with MSI-H/dMMR colorectal cancer experienced an objective response rate of 32%. The patients had previously failed a fluoropyrimidine, oxaliplatin and irinotecan regimen. The results were roughly equivalent to those produced by BMS’s Opdivo and Merck’s Keytruda. In the US, Tracon Pharma partners the candidate with the two China pharmas

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!